For patients who start on 2.4 mg and then hit a frustrating plateau, or for those with a very high baseline BMI who may need a stronger metabolic push, this creates a legitimate, evidence-based escalation path rather than forcing an early switch to another drug class, Balazs, who was not involved in the study, told Fox News Digital
This dual-modality strategy leverages the metabolic benefits of GLP-1 receptor agonists with the targeted fat-reduction effects of body contouring devices, delivering transformative results without surgery
doi: 10.1146/annurev-publhealth-040617-013638
We believe that wellness starts with trust, which is why our products contain no hidden ingredients and feature transparent labels
Warnings: If pregnant or breastfeeding, consult your healthcare professional before use